Research Projects
(1) National Natural Science Foundation of China, No.82071202, 2021-01-01 to 2024-12-31
(2) National Natural Science Foundation of China, No.81603113, 2017-01-01 to 2019-12-31
(3) Department of Science and Technology of Jiangsu Province, Natural Science Foundation of Jiangsu Province, No.BK20150705, 2015-07-01 to 2018-06-30
1. New drug target discovery and innovative drug research for neurodegenerative diseases such as Alzheimer's disease
2. New drug target discovery and innovative drug research for mental illnesses such as depression and anxiety
3. Evaluation and mechanism of drug addiction
Research Projects
(1) National Natural Science Foundation of China, No.82071202, 2021-01-01 to 2024-12-31
(2) National Natural Science Foundation of China, No.81603113, 2017-01-01 to 2019-12-31
(3) Department of Science and Technology of Jiangsu Province, Natural Science Foundation of Jiangsu Province, No.BK20150705, 2015-07-01 to 2018-06-30
1. Ren XQ, Huang X, Xing SY, Long Y, Yuan DH, Hong H, Tang SS*. Neuroprotective effects of novel compound FMDB on cognition, neurogenesis and apoptosis in APP/PS1 transgenic mouse model of Alzheimer's disease. Neurochem Int. 2023, 165: 105510. (IF: 4.297)
2. Chen F, Fang S, Du Y, Ghosh A, Reed MN, Long Y, Suppiramaniam V, Tang S*, Hong H*. CRISPR/Cas9-mediated CysLT1R deletion reverses synaptic failure, amyloidosis and cognitive impairment in APP/PS1 mice. Aging (Albany NY). 2021, 13(5):6634-6661. (IF: 5.955)
3. Chen F, Ghosh A, Lin J, Zhang C, Pan Y, Thakur A, Singh K, Hong H*, Tang S*. 5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer’s disease. Brain Behav Immun. 2020, 88: 844-855. (IF:7.217)
4. Tang SS*#, Ren Y#, Ren XQ, Cao JR, Hong H, Ji H, Hu QH*. ERα and/or ERβ activation ameliorates cognitive impairment, neurogenesis and apoptosis in type 2 diabetes mellitus mice. Exp Neuro. 2019, 311: 33-43. (IF: 5.33)
5. Chen F#, Yu XB#, Meng GL, Mei ZL, Du YF, Sun HB, Reed MN, Kong LY, Suppiramaniam V, Hong H*, Tang SS*. Hippocampal Genetic Knockdown of PPARδ Causes Depression-Like Behaviors and Neurogenesis Suppression. Int J Neuropsychopharmacol. 2019, 22 (6), 372-382. (IF:5.176)
6. Wu X, Lv YG, Du YF, Hu M, Reed MN, Long Y, Suppiramaniam V, Hong H*, Tang SS*. Inhibitory effect of INT-777 on lipopolysaccharide-induced cognitive impairment, neuroinflammation, apoptosis, and synaptic dysfunction in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2019, 88:360-374. (IF: 5.067)
7. Wu X, Lv YG, Du YF, Chen F, Reed MN, Hu M, Suppiramaniam V, Tang SS*, Hong H*. Neuroprotective effects of INT-777 against Aβ1-42-induced cognitive impairment, neuroinflammation, apoptosis, and synaptic dysfunction in mice. Brain Behav Immun. 2018, 73: 533-545. (IF: 6.17)
8. Tang SS*, Ren Y, Xu LJ, Cao JR, Hong H, Ji H, Hu QH*. Activation of ERα and/or ERβ ameliorates cognitive impairment and apoptosis in streptozotocin-induced diabetic mice. Horm Behav. 2018, 105: 95-103. (IF：4.418)
9. Wang H, Chen F, Du YF, Long Y, Reed MN, Hu M, Suppiramaniam V, Hong H*, Tang SS*. Targeted inhibition of RAGE reduces amyloid-β influx across the blood-brain barrier and improves cognitive deficits in db/db mice. Neuropharmacology. 2018, 131:143-153. (IF：4.367)
10. Li DD, Xie H, Du YF, Long Y, Reed MN, Hu M, Suppiramaniam V, Hong H*, Tang SS*. Antidepressant-like effect of zileuton is accompanied by hippocampal neuroinflammation reduction and CREB/BDNF upregulation in lipopolysaccharide-challenged mice. J Affect Disord. 2017, 227:672-680. (IF：3.786)
